公开(公告)号：WO2023092089A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/080167

申请日：2022-11-18

Applicant: KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY) ,  K2B THERAPEUTICS, INC.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：WO2019009593A2

公开(公告)日：2019-01-10

申请号：PCT/KR2018/007526

申请日：2018-07-03

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： CHUNG, Hak Suk ,  JI, Yu Hyun ,  AN, Jin Su ,  KWON, Ick Chan ,  YANG, Eun Gyeong

IPC: C12N15/74 ,  C12N9/14 ,  C12N9/16 ,  C12P19/04

Abstract: A bacterium that constitutively produces monophosphoryl lipid A (MLA) and a method of producing MLA by using the bacterium may simply produce MLA and a derivative thereof without acid hydrolysis, reduce a probability of natural mutation, and increase yields of MLA and a derivative thereof by constitutive expression of the MLA and derivative thereof.

公开(公告)号：WO2006075881A1

公开(公告)日：2006-07-20

申请号：PCT/KR2006/000130

申请日：2006-01-12

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  KWON, Ick Chan ,  JEONG, Seo Young ,  KIM, In-san ,  CHUNG, Hesson ,  SEO, Sang Bong ,  PARK, Jae Hyung ,  KWON, Seunglee ,  KIM, Kwangmyung ,  KIM, Jong-ho

Inventor： KWON, Ick Chan ,  JEONG, Seo Young ,  KIM, In-san ,  CHUNG, Hesson ,  SEO, Sang Bong ,  PARK, Jae Hyung ,  KWON, Seunglee ,  KIM, Kwangmyung ,  KIM, Jong-ho

IPC: A61K9/00

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/5123 ,  A61K9/5161 ,  A61K47/61

Abstract: Disclosed are a cholanic acid-chitosan complex forming self-aggregates and a preparation method thereof, and more particularly, a cholanic acid-chitosan complex which is composed of hydrophobic cholanic acid and hydrophilic chitosan and forms self-aggregates in an aquatic environment, and a method of preparing the cholanic acid- chitosan complex. The cholanic acid-chitosan complex forms self -aggregates, which prolong the drug release period, enhance the selectivity of the complex for tumor tissue, and greatly increase drug loading content when a drug is incorporated into the self -aggregates, compared to chemical bonding, which limits drug incorporation. Thus, the cholanic acid-chitosan complex is useful for anticancer chemotherapy.

Abstract translation: 公开了形成自聚集体的胆酸 - 壳聚糖复合物及其制备方法，更具体地说，涉及由疏水性胆酸和亲水性壳聚糖构成并在水生环境中形成自聚集体的胆酸 - 壳聚糖复合物， 制备胆酸 - 壳聚糖复合物的方法。 与化学键合相比，胆酸 - 壳聚糖复合物形成自聚集体，其延长药物释放时间，增强复合物对肿瘤组织的选择性，并且当药物掺入自聚集体时大大增加药物负载量， 这限制了药物并入。 因此，胆酸 - 壳聚糖复合物可用于抗癌化疗。

公开(公告)号：EP4197559A1

公开(公告)日：2023-06-21

申请号：EP20949578.7

申请日：2020-08-14

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Sun Hwa ,  KWON, Ick Chan ,  KIM, In-San ,  KIM, Kwangmeyung ,  YANG, Yoosoo ,  KO, Young-ji

IPC: A61K47/64 ,  A61K47/65 ,  A61K31/713 ,  A61P35/00 ,  C12N15/115

Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.

公开(公告)号：EP1383539A1

公开(公告)日：2004-01-28

申请号：EP02758920.9

申请日：2002-08-14

Applicant: Korea Institute of Science and Technology ,  Jakwang Co., Ltd.

Inventor： KWON, Ick Chan ,  KIM, In-San ,  JEONG, Seo Young ,  CHUNG, Hesson ,  CHO, Yong Woo ,  SON, Yoen Ju,106-1404 Sinkongduk samsung Apt. ,  PARK, Chong Rae,Ga-102 Seoul Univ. kyosu Apt. ,  SEO, Sang, Bong

IPC: A61K47/48

CPC classification number: A61K31/704 ,  A61K47/61 ,  A61K47/6907

Abstract: The present invention relates to an anticancer drug-chitosan complex forming self-aggregates and the preparation method thereof. More precisely, the present invention relates to the anticancer drug-chitosan complex forming self-aggregates in aqueous media composed of a hydrophobic anticancer agent and a hydrophilic chitosan, and the preparation method thereof. The anticancer drug-chitosan complex of the present invention not only works selectively against target tumor tissue but also continues to release the medicine over a long period of time. Besides, the anticancer drug-chitosan complex could have greater amount of drug by adding the anticancer drug into self-aggregates, which is generally limited by chemical bond. Therefore, the anticancer drug-chitosan complex of the present invention can be effectively used for the cancer chemotherapy.

公开(公告)号：EP3649244A2

公开(公告)日：2020-05-13

申请号：EP18828686.8

申请日：2018-07-03

Applicant: Korea Institute of Science and Technology

Inventor： CHUNG, Hak Suk ,  JI, Yuhyun ,  AN, Jinsu ,  KWON, Ick Chan ,  YANG, Eun Gyeong

IPC: C12N15/74 ,  C12N9/14 ,  C12N9/16 ,  C12P19/04

公开(公告)号：EP3459567A1

公开(公告)日：2019-03-27

申请号：EP18164779.3

申请日：2018-03-28

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Kwangmeyung ,  KWON, Ick Chan ,  PARK, Juho

IPC: A61K47/65 ,  A61K47/69

Abstract: Disclosed is a drug conjugate as a prodrug that is degraded by cathepsin B specifically expressed in tumor tissues to release doxorubicin. The drug conjugate can form self-assembled nanoparticles. In addition, the drug conjugate specifically responds to and is activated in tumor cells. Therefore, the use of the drug conjugate eliminates the incidence of side effects (for example, cell damage and apoptosis) during the course of cancer prevention or treatment.

公开(公告)号：EP4340893A1

公开(公告)日：2024-03-27

申请号：EP22844608.4

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00

公开(公告)号：EP4198512A1

公开(公告)日：2023-06-21

申请号：EP21856250.2

申请日：2021-08-12

Applicant: Korea Institute of Science and Technology ,  Korea University Research and Business Foundation

Inventor： RYU, Ju Hee ,  KWON, Ick Chan ,  KIM, Kwangmeyung ,  KIM, Han Young ,  KIM, Eun-sun

IPC: G01N33/68 ,  G01N33/58 ,  C12Q1/25 ,  A61K47/64 ,  A61P35/00

Abstract: The present disclosure relates to a cancer cell-specific complex for targeting cancer. The complex for targeting cancer according to the present disclosure includes EGF, but is affected more by lysosomal activity rather than the EGFR signaling pathway, and thus can overcome the shortcomings of the existing EGF therapy-based diagnostic and therapeutic compositions and provide successfully personalized and improved effects of treating, preventing and alleviating cancer.
A diagnostic composition according to the present disclosure enables the prediction of the anticancer performance of a therapeutic composition of the present disclosure in a subject, and thus enables anticancer treatment to be designed stably.

公开(公告)号：EP1835888B1

公开(公告)日：2017-07-12

申请号：EP06702900.9

申请日：2006-01-12

Applicant: Korea Institute of Science and Technology

Inventor： KWON, Ick Chan ,  JEONG, Seo Young ,  KIM, In-san ,  CHUNG, Hesson ,  SEO, Sang Bong Jakwang Co., Ltd. ,  PARK, Jae Hyung ,  KWON, Seunglee ,  KIM, Kwangmyung ,  KIM, Jong-ho

IPC: A61K9/19 ,  A61K47/28 ,  A61K47/36 ,  A61K31/337

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/5123 ,  A61K9/5161 ,  A61K47/61